Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
SeeTrue Technology
company
About
SeeTrue Technology is a biotechnology company that develops microcapillaries.
- 1 - 10
Details
- Last Funding Type
- Pre-seed
- Last Funding Money Raised
- $100K
- Industries
- Biotechnology,Medical Device
- Founded date
- Jan 1, 2018
- Number Of Employee
- 1 - 10
- Operating Status
- Active
SeeTrue Technology reduces clogging, cell adherence, tissue damage, tip visibility, and directional targeted injection. They have an injection needle that transforms the biomedical industry. They reduce the adherence of cells to the inner surface of the microneedle.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
3
$325K
SeeTrue Technology has raised a total of
$325K
in funding over 2 rounds. Their latest funding was raised on
Jan 31, 2023 from a Non-Equity Assistant round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 31, 2023 | Non-Equity Assistant | — | 1 |
TEDCO
|
— | Detail |
| Jan 3, 2023 | Pre-seed | $100K | 1 |
TEDCO
|
— | Detail |
| Mar 2, 2020 | Grant | $225K | 1 |
National Science Foundation
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
3
2
SeeTrue Technology is funded by 2 investors.
TEDCO
and National Science Foundation
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
TEDCO
|
Yes | Non-Equity Assistant |
|
National Science Foundation
|
Yes | Grant |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
